TITLE

AVANTOGEN'S HAWAII BIOTECH GETS WALTER REED TRIAL SUPPORT

PUB. DATE
October 2008
SOURCE
Worldwide Biotech;Oct2008, Vol. 20 Issue 10, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Avantogen has obtained additional support for the Dengue vaccine program developed by Hawaii Biotech Inc., in which Avantogen holds an investment stake. Testing of the Dengue vaccine will be conducted at the clinical trials centre of the U.S. Walter Reed Army Institute of Research (WRAIR), an institution that was noted to be recognised for its competency in emerging infectious disease and its considerable experience with Dengue fever.
ACCESSION #
34517490

 

Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;6/25/2008, Vol. 19 Issue 123, p8 

    This section offers clinical news briefs in the biopharmaceutical industry as of June 25, 2008. Objectives of a Phase IIa trial for the treatment of rheumatoid arthritis were achieved by Active Biotech AB and MediGene AG. Avantogen Ltd. and Hawaii Biotech Inc. have started Phase I trials for...

  • Dengue Vaccine Clears Major Trial Hurdle. ASCHWANDEN, CHRISTIE // Discover;Jan/Feb2015, Vol. 36 Issue 1, p30 

    The article reports that a vaccine for dengue, which at its most severe presents as dengue hemorrhagic fever, has passed a major trial milestone with the release of results of a clinical trial in Latin America which involved over 20,000 children.

  • HAWAII BIOTECH BEGINS PHASE 1 TRIAL FOR DENGUE VACCINE.  // Biotech Business;Oct2009, Vol. 22 Issue 10, p7 

    The article reports on the phase 1 clinical research of monovalent dengue vaccine by Hawaii Biotech Inc. in 2009. It is said that the vaccine is the first recombinant dengue vaccine to go through such study which will determine its safety, range of dosage to be used and possible side effects. It...

  • Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. Byers, Anthony M.; Broder, Ryan; Haupfear, Kelly; Timiryasova, Tatyana M.; Hu, Branda T.; Boaz, Mark; Warren, William L.; Jackson, Nicholas; Moser, Janice M.; Guy, Bruno // Open Forum Infectious Diseases;Fall2015, Vol. 2 Issue 4, p1 

    Background. Recent trials of recombinant, live-attenuated chimeric yellow fever-dengue tetravalent dengue vaccine (CYD-TDV) demonstrated efficacy against symptomatic, virologically confirmed dengue disease with higher point estimates of efficacy toward dengue virus (DENV)3 and DENV4 and moderate...

  • Evaluating Dengue Vaccines. Friedrich, M. J. // JAMA: Journal of the American Medical Association;4/20/2011, Vol. 305 Issue 15, p1527 

    The article references a study by R. Mahoney and colleagues, published in a 2011 issue of "PLoS Medicine" about issues that need to be addressed for regulatory review and licensure of a vaccine for dengue fever, including holding clinical trials in different countries, and providing training and...

  • CLINIC ROUNDUP.  // BioWorld Today;2/26/2009, Vol. 20 Issue 37, p6 

    This section offers news briefs concerning the biotechnology industry. Cerimon Pharmaceuticals Inc. has chosen its first subjects for its once-daily topical diclofenac sodium patch Phase III program. Hawaii Biotech Inc. announced the successful Phase I trial findings of its West Nile virus...

  • Pharma: Clinic Roundup.  // BioWorld Today;9/12/2012, Vol. 23 Issue 177, p6 

    The article reports on the positive results obtained by Sanofi Pasteur from a clinical trial of its vaccine candidate against dengue fever.

  • Sanofi Pasteur releases dengue vaccine results.  // Infectious Disease News;Jun2014, Vol. 27 Issue 6, p24 

    The article reports on the success of the Phase three study of the dengue vaccine candidate by pharmaceutical company Sanofi Pasteur Inc., which showed that the vaccine significantly reduced cases of dengue disease among Asian children.

  • Financings Roundup.  // BioWorld Today;8/21/2008, Vol. 19 Issue 163, p6 

    The article reports that the private placement of stock by Avantogen Ltd was able to raise A$1 million. Twenty million new ordinary shares is being sold by company for A5 cents each. According to the company, proceeds from the placement will be used to increase its holdings in Hawaii Biotech...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics